Both dapagliflozin and empagliflozin have favorable effects on heart failure; however, dapagliflozin is characterized by a longer pharmacological effect and lower SGLT2:SGLT1 receptor selectivity (i.e., higher selectivity of SGLT1 receptors, thereby reducing postprandial blood glucose variations) than empagliflozin [31,32]. This evidence concerns the gene SLC5A2 and heart failure.